Analysts See Strong Upside Potential in Insurance and Specialty Chemical Stocks

Indian stock markets are expected to remain volatile amid mixed global cues, rising crude oil prices and sector-specific movements. However, analysts continue to identify selective opportunities in fundamentally strong companies that offer healthy earnings visibility and long-term growth potential.

According to Shrikant Chouhan, investors can consider buying SBI Life Insurance while adding Galaxy Surfactants on declines for medium-term gains. Both companies are backed by strong business models, improving financial performance and sector leadership.

SBI Life Insurance Remains a Strong Long-Term Bet

Recommendation: BUY

• CMP: ₹1,878
• Fair Value: ₹2,500
• Resistance: ₹1,905–1,940
• Support: ₹1,855–1,825

SBI Life Insurance continues to remain one of the preferred picks in the financial services space due to its strong distribution network, improving premium growth and healthy profitability metrics.

Backed by parent State Bank of India, SBI Life has built a dominant presence in India’s life insurance sector with a strong focus on retail protection, savings and investment-linked products.

Company Crosses Major Milestone

During FY26, SBI Life crossed the ₹1 trillion milestone in Gross Written Premium (GWP), registering a strong 19% year-on-year growth. The company currently commands nearly 22.9% market share among private life insurers based on individual rated premium.

Its diversified product portfolio includes:

• Unit Linked Insurance Plans (ULIPs)
• Participating plans
• Non-participating products
• Pure protection insurance solutions

The company is also gradually shifting toward higher-margin protection and traditional savings products, which could support profitability over the long term.

Q4 Performance Highlights Steady Growth

SBI Life delivered a stable operational performance during the March quarter despite industry-wide regulatory changes and margin pressures.

Key Q4 FY26 Highlights

• Net premium income rose 16% YoY to ₹27,684 crore
• Net profit stood at ₹804.6 crore
• Annualised Premium Equivalent (APE) increased 5.5%
• Full-year New Business Premium surged 20%
• Value of New Business (VNB) margin remained healthy at 28.4%

Management remains optimistic about FY27 growth prospects and has guided for 13–14% APE growth in the coming financial year.

GST Benefits Expected to Boost Demand

The company believes recent GST exemptions on individual insurance policies are likely to improve affordability and increase insurance penetration across India.

Management also highlighted its focus on:

• Expanding protection products
• Increasing non-PAR product mix
• Maintaining stable VNB margins
• Improving operational efficiency

The company’s solvency ratio of 1.90x remains comfortably above the regulatory requirement, providing sufficient room for future expansion.

Strong April Business Momentum

SBI Life reported impressive business momentum in April 2026, reflecting healthy demand trends across retail and group insurance segments.

April 2026 Business Update

• Overall APE growth: 30% YoY
• Individual APE growth: 18% YoY
• Group APE growth: 244% YoY
• Number of policies grew 11%
• Average ticket size increased 6%

Analysts believe SBI Life’s strong market positioning, trusted brand name and extensive bancassurance network could continue to drive sustainable growth over the medium term.

Galaxy Surfactants: Specialty Chemical Player With Global Presence

Recommendation: ADD

• CMP: ₹1,885
• Fair Value: ₹2,150
• Resistance: ₹1,940–2,000
• Support: ₹1,840–1,770

Galaxy Surfactants is one of India’s leading specialty chemical companies focused on personal care, home care and wellness ingredients.

The company manufactures specialty surfactants and performance ingredients used in products such as:

• Shampoos
• Soaps
• Face wash
• Detergents
• Conditioners
• Skincare formulations

Unlike commodity chemical businesses, Galaxy operates in a differentiated niche with innovation-driven products and sticky global customer relationships.

Strong International Footprint

Galaxy Surfactants currently serves more than 1,500 customers across over 80 countries through seven manufacturing facilities located in India, Egypt and the United States.

Its diversified geographic footprint offers:

• Better supply chain flexibility
• Reduced concentration risk
• Stronger global customer access
• Long-term export growth opportunities

The company’s Vision 2030 strategy focuses on strengthening its presence in North America, Europe, Latin America and Asia-Pacific markets.

Specialty Products Driving Margin Expansion

The company currently offers over 215 product grades, including:

• 47+ performance surfactants
• 168+ specialty care products

Analysts believe the specialty chemicals segment could become a key earnings driver due to:

• Higher profit margins
• Premium product positioning
• Strong customer retention
• Innovation-led growth

Galaxy’s strong research and development capabilities are supported by:

• 100+ scientists
• Multiple pilot plants
• Application centers
• More than 100 patents and filings

Temporary Challenges, Strong Long-Term Outlook

Recent earnings were impacted by:

• Elevated fatty alcohol prices
• Weakness in AMET markets
• Customer reformulation at a key India account
• US tariff-related disruptions

However, analysts believe these challenges are cyclical rather than structural.

The long-term growth story remains intact, supported by:

• Specialty product mix improvement
• Recovery in domestic demand
• Global expansion strategy
• Increasing penetration among FMCG clients
• Operational efficiencies

Market Outlook

Analysts believe both SBI Life and Galaxy Surfactants offer attractive opportunities for investors seeking quality businesses with strong long-term compounding potential.

While SBI Life stands out as a stable financial sector play benefiting from rising insurance penetration, Galaxy Surfactants offers exposure to the premium specialty chemicals segment with strong export potential and innovation-driven growth.

Investors are advised to remain selective and adopt a staggered investment strategy amid ongoing market volatility.